Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and ...

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing ...

Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ETAccess the webcast hereCarlsbad, CA, Feb. 09, 2026 ...

Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor. vTv to ...

250 Pages Atopic Dermatitis Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider According to Fact MR’s recent market research, sales of Atopic Dermatitis to swell at ...

HIGH POINT, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for ...

The Food and Drug Administration has accepted a new drug application (NDA) for roflumilast, a topical phosphodiesterase type 4 (PDE4) inhibitor for treating psoriasis in adults and adolescents, ...

Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...

The US Food and Drug Administration's March 21 approval of Celgene's Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase-4 (PDE4), is the first regulatory nod given to a member of ...

DelveInsight’s PDE4 Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging PDE4 inhibitors, market share of individual therapies, and current ...